REAL QULIPTA®
PATIENTS
Kelsi
Real QULIPTA patient
- 36 years old
- Recently adopted an 8-year-old girl
- Enjoys watching her kids at soccer games or dance recitals
BEFORE QULIPTA
“I have stories on stories on stories of times that migraine has ruined something for me.”
- Diagnosed with episodic migraine at an early age
- Was ready and willing to try a preventive, but wasn't aware it was an option
- Reported experiencing ~4 migraine days per month before starting QULIPTA
- Tried a few different prescription acute treatments in high school, but they weren't right for her
- Relied on OTC medications through college
WITH QULIPTA
“QULIPTA has helped reduce the amount of migraine attacks that I'm having. I'm so thankful for QULIPTA.”
- Started QULIPTA as her first preventive
- Feels QULIPTA has made a significant difference in her life
In clinical trials, QULIPTA 60 mg reduced MMD in EM and CM patients across 12 weeks.
In the ADVANCE EM trial, QULIPTA 60 mg improved function, as measured by AIM-D PDA, across 12 weeks.
AIM-D PDA=Activity Impairment in Migraine-Diary Performance of Daily Activities; CM=chronic migraine; EM=episodic migraine; MMD=Monthly Migraine Days.
Individual results may vary. Kelsi is an actual QULIPTA patient who was on prescribed therapy when she provided this testimonial. Changes in therapy status may have occurred since that time. Kelsi was compensated by AbbVie for sharing her story.
Casey
Real QULIPTA patient
- 57 years old
- Works as an ophthalmology technician
- Enjoys walking and listening to podcasts
BEFORE QULIPTA
“I wish I would have started on medication earlier. I wish it didn’t have to get to the point that it got to.”
- Started experiencing migraine attacks in her 40s
- Wasn't meeting her treatment goals and was seeking a tolerable preventive that could significantly reduce her migraine days
- Reported experiencing 12-16 migraine days per month before starting QULIPTA
- Didn’t seek diagnosis or treatment for years due to insurance issues
- Tried multiple acute and preventive treatments with mixed results
WITH QULIPTA
“I experience fewer migraine days, which helps me do more things and keep more plans.”
- Started QULIPTA after failing on 2 prior preventive therapies
- Feels QULIPTA has made a positive impact on her social and family life
In clinical trials, QULIPTA 60 mg reduced MMD in EM and CM patients across 12 weeks.
In the ADVANCE EM trial, QULIPTA 60 mg improved function, as measured by AIM-D PDA, across 12 weeks.
AIM-D PDA=Activity Impairment in Migraine-Diary Performance of Daily Activities;
CM=chronic migraine; EM=episodic migraine; MMD=Monthly Migraine Days.
Individual results may vary. Casey is an actual QULIPTA patient who was on prescribed therapy when she provided this testimonial. Changes in therapy status may have occurred since that time. Casey was compensated by AbbVie for sharing her story.
Latoya
Real QULIPTA patient
- 46 years old
- Mother of 3 boys
- Enjoys reading and hosting art classes
BEFORE QULIPTA
“Having several migraine days a month and having to be a mother, a sister, a daughter… it was very difficult.”
- Diagnosed with migraine in 2001 during pregnancy, but dealt with symptoms for many years prior
- Was seeking a treatment that helped reduce breakthrough attacks
- Reported experiencing 10-15 migraine days per month before starting QULIPTA
- Tried multiple prescription and OTC treatments but discontinued due to intolerability
WITH QULIPTA
“I was able to start going to more of my kids' soccer games and band performances.”
- Started QULIPTA in 2023
- Feels QULIPTA reduces her migraine days, allowing her to show up for her family more often
In clinical trials, QULIPTA 60 mg reduced MMD in EM and CM patients across 12 weeks.
In the ADVANCE EM trial, QULIPTA 60 mg improved function, as measured by AIM-D PDA, across 12 weeks.
AIM-D PDA=Activity Impairment in Migraine-Diary Performance of Daily Activities;
CM=chronic migraine; EM=episodic migraine; MMD=Monthly Migraine Days.
Individual results may vary. Latoya is an actual QULIPTA patient who was on prescribed therapy when she provided this testimonial. Changes in therapy status may have occurred since that time. Latoya was compensated by AbbVie for sharing her story.